Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)

BACKGROUND: Few prospective studies have used liquid biopsy testing in RAS-mutant metastatic colorectal cancer (mCRC), and its clinical significance remains unknown. Therefore, this study aimed to carry out a biomarker analysis by liquid biopsy using updated data of the phase II trial of FOLFOXIRI p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunakawa, Y., Satake, H., Usher, J., Jaimes, Y., Miyamoto, Y., Nakamura, M., Kataoka, M., Shiozawa, M., Takagane, A., Terazawa, T., Watanabe, T., Ishiguro, K., Tanaka, C., Takeuchi, M., Fujii, M., Danenberg, K., Danenberg, P.V., Lenz, H.-J., Sekikawa, T., Ichikawa, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271512/
https://www.ncbi.nlm.nih.gov/pubmed/35688061
http://dx.doi.org/10.1016/j.esmoop.2022.100512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271512/
https://www.ncbi.nlm.nih.gov/pubmed/35688061
http://dx.doi.org/10.1016/j.esmoop.2022.100512

Ejemplares similares